Seminars in nuclear medicine最新文献

Advances in Endocrine Tumor PET Imaging Targeting CXCR4 and GLP-1. 靶向CXCR4和GLP-1的内分泌肿瘤PET成像研究进展

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-05-29 DOI: 10.1053/j.semnuclmed.2025.05.001

Esther Mena, Liza Lindenberg, Peter Herscovitch, Samira M Sadowski, Peter L Choyke

{"title":"Advances in Endocrine Tumor PET Imaging Targeting CXCR4 and GLP-1.","authors":"Esther Mena, Liza Lindenberg, Peter Herscovitch, Samira M Sadowski, Peter L Choyke","doi":"10.1053/j.semnuclmed.2025.05.001","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2025.05.001","url":null,"abstract":"Molecular imaging has experienced significant advances in the areas of imaging probes and technology, enabling the detection of tumors at earlier stages and more accurately identifying extent of disease. To better characterize lesions, nuclear medicine modalities utilize molecular imaging agents targeting specific pathways and cell surface molecules to improve both sensitivity and specificity. In the field of endocrinology, tumors encompass a wide spectrum of aggressiveness ranging from indolent, well differentiated tumors to highly aggressive cancers. Thus, in recent years, new molecular imaging biomarkers have been developed for noninvasively assessing different types of hormone-producing tumors. For instance, 68Ga-PentixaFor is a novel PET imaging agent targeting the C-X-C chemokine receptor type 4 (CXCR4) with proven utility in various malignancies, and has also shown multifunctionality in detecting endocrine pathologies, such as primary aldosteronism, adrenocorticotropic hormone (ACTH)-producing pituitary adenomas and ACTH-independent cortisol-producing adrenal adenomas. Another novel receptor-targeted radiotracer using the glucagon-like peptide-1 receptor (GLP-1R) analog, Exendin-4 has recently developed to preoperatively localize insulinomas, arising from pancreatic beta cells. This review presents an overview of new developments and potential clinical implementation of CXCR4- and Exendin- based radiotracers for imaging applications in endocrinology.","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

¹⁸F-FDG PET for Dementia Evaluation: Co-pathologies, New Diseases, and Its Roles in the Era of Antiamyloid Treatment. 18F-FDG PET用于痴呆评估：共病、新疾病及其在抗淀粉样蛋白治疗时代的作用。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-05-29 DOI: 10.1053/j.semnuclmed.2025.04.007

Tanyaluck Thientunyakit, Weerasak Muangpaisan, Satoshi Minoshima

{"title":"18F-FDG PET for Dementia Evaluation: Co-pathologies, New Diseases, and Its Roles in the Era of Antiamyloid Treatment.","authors":"Tanyaluck Thientunyakit, Weerasak Muangpaisan, Satoshi Minoshima","doi":"10.1053/j.semnuclmed.2025.04.007","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2025.04.007","url":null,"abstract":"Dementia, which impairs a person's cognition and ability in daily tasks and is often caused by neurodegenerative disorders, remains one of the most challenging neuropsychiatric conditions. The prevalence of dementia has been steadily increasing in aging societies. Recently, antiamyloid treatment has been developed and approved for the treatment of Alzheimer's disease (AD), which is known as the major cause of dementia. Such therapeutic developments have accelerated the use of in vivo biomarkers in research, clinical trials, and clinical practice. Past and recent developments of several biomarkers, including 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), have played a pivotal role in understanding the underlying mechanisms of dementing disorders and accelerating progress in both research and clinical practice, leading to more accurate clinical diagnosis, recognition of co-pathologies, better understanding of new diseases, treatment planning, and response evaluation. This article reviews the roles of brain FDG PET, one of the well-established imaging biomarkers, as a valuable tool for studying brain metabolism and its applications in clinical and research settings, particularly for the treatment of dementia.","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targets for Molecular Imaging of Neuroendocrine Tumors (NETs): An Overview and Update. 神经内分泌肿瘤（NETs）分子成像靶点：综述与最新进展。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-05-28 DOI: 10.1053/j.semnuclmed.2025.04.003

Esmail Jafari, Majid Assadi, Meysam Nasiri, Hojjat Ahmadzadehfar

{"title":"Targets for Molecular Imaging of Neuroendocrine Tumors (NETs): An Overview and Update.","authors":"Esmail Jafari, Majid Assadi, Meysam Nasiri, Hojjat Ahmadzadehfar","doi":"10.1053/j.semnuclmed.2025.04.003","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2025.04.003","url":null,"abstract":"Neuroendocrine neoplasms (NENs) represent a diverse group of tumors originating from neuroendocrine cells, characterized by their unique biological behavior and clinical manifestations. The incidence of neuroendocrine tumors (NETs) has been rising, necessitating effective diagnostic and therapeutic strategies. Molecular imaging, particularly through techniques such as PET and SPECT, plays a pivotal role in the management of NETs. This review highlights the significance of somatostatin receptor imaging in the initial diagnostic work-up, staging, and treatment planning for NETs, emphasizing the utility of radiopharmaceuticals like [68Ga]Ga-DOTATATE and [68Ga]Ga-DOTA-LM3. These agents demonstrate high sensitivity and specificity, allowing for accurate delineation of disease extent and identification of occult primary tumors. Furthermore, the review discusses the emerging role of nonsomatostatin receptor targets, such as glucose metabolism and fibroblast activation protein, in enhancing the diagnostic capabilities of molecular imaging. The integration of advanced imaging modalities, including dual-tracer approaches, is explored for their potential to refine therapeutic strategies and improve patient outcomes. As the field of molecular imaging continues to evolve, ongoing research and clinical trials are essential to validate the efficacy and safety of novel imaging agents and techniques, ultimately enhancing the management of patients with neuroendocrine tumors.","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence Augmented Cerebral Nuclear Imaging. 人工智能增强脑核成像。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-05-28 DOI: 10.1053/j.semnuclmed.2025.05.005

Geoffrey M Currie, K Elizabeth Hawk

{"title":"Artificial Intelligence Augmented Cerebral Nuclear Imaging.","authors":"Geoffrey M Currie, K Elizabeth Hawk","doi":"10.1053/j.semnuclmed.2025.05.005","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2025.05.005","url":null,"abstract":"Artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), has significant potential to advance the capabilities of nuclear neuroimaging. The current and emerging applications of ML and DL in the processing, analysis, enhancement and interpretation of SPECT and PET imaging are explored for brain imaging. Key developments include automated image segmentation, disease classification, and radiomic feature extraction, including lower dimensionality first and second order radiomics, higher dimensionality third order radiomics and more abstract fourth order deep radiomics. DL-based reconstruction, attenuation correction using pseudo-CT generation, and denoising of low-count studies have a role in enhancing image quality. AI has a role in sustainability through applications in radioligand design and preclinical imaging while federated learning addresses data security challenges to improve research and development in nuclear cerebral imaging. There is also potential for generative AI to transform the nuclear cerebral imaging space through solutions to data limitations, image enhancement, patient-centered care, workflow efficiencies and trainee education. Innovations in ML and DL are re-engineering the nuclear neuroimaging ecosystem and reimagining tomorrow's precision medicine landscape.","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Radiopharmaceutical Tools in Imaging. 新放射药物成像工具。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-05-26 DOI: 10.1053/j.semnuclmed.2025.05.002

Dirk Bender

引用次数: 0

PET/CT in the Imaging of CNS Tumors. PET/CT在中枢神经系统肿瘤成像中的应用。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-05-21 DOI: 10.1053/j.semnuclmed.2025.04.002

Katarzyna Barańska, Katarzyna Niemas, Kacper Pełka, Jolanta Kunikowska

引用次数: 0

FAPI PET Versus FDG PET/CT in Gastrointestinal Cancers: An Overview. FAPI PET与FDG PET/CT在胃肠道癌症中的对比：综述。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-05-20 DOI: 10.1053/j.semnuclmed.2025.04.006

Zhaoguo Lin, Pawel Rasinski, Ted Nilsson, Maria Holstensson, Yangmeihui Song, August Blomgren, Warissara Jutidamrongphan, Kalyani Pandya, Jimin Hong, Axel Rominger, Kuangyu Shi, Rimma Axelsson, Xiaoli Lan, Robert Seifert

{"title":"FAPI PET Versus FDG PET/CT in Gastrointestinal Cancers: An Overview.","authors":"Zhaoguo Lin, Pawel Rasinski, Ted Nilsson, Maria Holstensson, Yangmeihui Song, August Blomgren, Warissara Jutidamrongphan, Kalyani Pandya, Jimin Hong, Axel Rominger, Kuangyu Shi, Rimma Axelsson, Xiaoli Lan, Robert Seifert","doi":"10.1053/j.semnuclmed.2025.04.006","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2025.04.006","url":null,"abstract":"Fibroblast activation protein (FAP) is a type II transmembrane serine protease that is highly expressed in cancer-associated fibroblasts (CAFs) but absent in quiescent fibroblasts. Its overexpression is associated with poor prognosis in various cancers and contributes to treatment resistance. In recent years, radiolabeled FAP inhibitors (FAPI) for PET imaging have shown promising clinical value across a range of cancers. Gastrointestinal (GI) malignancies, which often exhibit a desmoplastic reaction with a high density of FAP-expressing CAFs, are particularly well-suited for FAPI PET. Given the limitations of [18F]FDG PET in GI cancers, such as low sensitivity in certain histological subtypes and high physiological background uptake, FAPI PET is expected to serve as a complementary method, potentially enhancing both diagnostic accuracy and treatment guidance. This review provides a comprehensive comparison of the clinical applications of FAPI PET and [18F]FDG PET in various GI cancers, including their value in diagnosis, staging, and treatment guidance. Additionally, this review summarizes studies on the expanding role of FAPI PET, including its use in assessing treatment response and predicting prognosis, aiming to provide insights into its potential contribution to the improved management of GI malignancies.","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cu^II-bis(thioureido) Complex: A Potential Radiotracer for Detecting Oxidative Stress and Neuroinflammation in Neurodegenerative Diseases. CuII-bis（硫脲）配合物：检测神经退行性疾病中氧化应激和神经炎症的潜在放射性示踪剂。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-05-12 DOI: 10.1053/j.semnuclmed.2025.03.008

Weiyuan Lin, Chongyi Huang, Zhiqiang Tan, Hao Xu, Weijun Wei, Lu Wang

{"title":"CuII-bis(thioureido) Complex: A Potential Radiotracer for Detecting Oxidative Stress and Neuroinflammation in Neurodegenerative Diseases.","authors":"Weiyuan Lin, Chongyi Huang, Zhiqiang Tan, Hao Xu, Weijun Wei, Lu Wang","doi":"10.1053/j.semnuclmed.2025.03.008","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2025.03.008","url":null,"abstract":"Neurodegenerative diseases, characterized by progressive neuronal degeneration and associated with neuroinflammation and oxidative stress, present significant challenges in diagnosis and treatment. This review explores the potential of copper(II)-bis(thiosemicarbazone) complexes, particularly Cu-ATSM, as a dual-purpose radiopharmaceutical for imaging and therapeutic interventions. Cu-ATSM exhibits unique redox-dependent retention in pathological microenvironments, driven by mitochondrial dysfunction and hyper-reductive states, which enables the noninvasive detection of oxidative stress via positron emission tomography (PET). Preclinical studies demonstrate its efficacy in mitigating neuroinflammation by suppressing glial activation, reducing the secretion of pro-inflammatory cytokines (e.g., TNF-α, MCP-1), and increasing the expression of neuroprotective metallothionein-1 (MT1). Some Clinical research reveals elevated ⁶⁴Cu-ATSM uptake in Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS) patients, correlating with disease severity and regional oxidative stress markers. Furthermore, Cu-ATSM derivatives show promise in modulating blood-brain barrier (BBB) permeability, enhancing amyloid-β clearance, and restoring copper homeostasis in ALS models. Despite these advances, limitations such as small cohort sizes and heterogeneity in clinical studies underscore the need for larger-scale validation. Multimodal imaging integrating PET and MRI, alongside novel structural analogs targeting Aβ plaques and redox imbalances, emerges as a strategic direction for future research. Collectively, Cu-ATSM represents a transformative tool for elucidating neuropathological mechanisms and advancing therapeutic strategies in neurodegenerative disorders.","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular Imaging for Response Assessment of Neuroendocrine Tumors (NET). 神经内分泌肿瘤反应评估的分子影像学研究。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-05-08 DOI: 10.1053/j.semnuclmed.2025.04.005

Martina Di Franco, Giuseppe Lamberti, Davide Campana, Valentina Ambrosini

{"title":"Molecular Imaging for Response Assessment of Neuroendocrine Tumors (NET).","authors":"Martina Di Franco, Giuseppe Lamberti, Davide Campana, Valentina Ambrosini","doi":"10.1053/j.semnuclmed.2025.04.005","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2025.04.005","url":null,"abstract":"Assessing treatment response in neuroendocrine tumors (NET) remains a significant challenge due to their typically indolent growth and heterogenity, the frequent occurrence of disease stabilization rather than tumor shrinkage after therapy, and the inherent limitations of conventional imaging criteria. While molecular imaging-primarily somatostatin receptor (SST) PET/CT-has improved lesion detection, the absence of standardized response criteria limits its clinical utility and prevents its use as full replacement of conventional imaging. Emerging strategies, including revised thresholds for dimensional changes, criteria evaluating different features, such as lesions' density and functional tumor volumes, offer potential improvements in response evaluation but require further validation for routine clinical implementation. This review examines the current challenges in assessing NET treatment response, evaluates the strengths and limitations of available imaging modalities, and discusses emerging approaches and future directions for optimizing therapeutic monitoring in the heterogeneous panorama of NET.","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Targets for Imaging in Nuclear Medicine. 核医学成像新靶点。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-05-06 DOI: 10.1053/j.semnuclmed.2025.04.004

Anita Brink, Diana Paez, Enrique Estrada Lobato, Roberto C Delgado Bolton, Peter Knoll, Aruna Korde, Adriana K Calapaquí Terán, Mohamad Haidar, Francesco Giammarile

{"title":"New Targets for Imaging in Nuclear Medicine.","authors":"Anita Brink, Diana Paez, Enrique Estrada Lobato, Roberto C Delgado Bolton, Peter Knoll, Aruna Korde, Adriana K Calapaquí Terán, Mohamad Haidar, Francesco Giammarile","doi":"10.1053/j.semnuclmed.2025.04.004","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2025.04.004","url":null,"abstract":"Nuclear medicine is rapidly evolving with new molecular imaging targets and advanced computational tools that promise to enhance diagnostic precision and personalized therapy. Recent years have seen a surge in novel PET and SPECT tracers, such as those targeting prostate-specific membrane antigen (PSMA) in prostate cancer, fibroblast activation protein (FAP) in tumor stroma, and tau protein in neurodegenerative disease. These tracers enable more specific visualization of disease processes compared to traditional agents, fitting into a broader shift toward precision imaging in oncology and neurology. In parallel, artificial intelligence (AI) and machine learning techniques are being integrated into tracer development and image analysis. AI-driven methods can accelerate radiopharmaceutical discovery, optimize pharmacokinetic properties, and assist in interpreting complex imaging datasets. This editorial provides an expanded overview of emerging imaging targets and techniques, including theranostic applications that pair diagnosis with radionuclide therapy, and examines how AI is augmenting nuclear medicine. We discuss the implications of these advancements within the field's historical trajectory and address the regulatory, manufacturing, and clinical challenges that must be navigated. Innovations in molecular targeting and AI are poised to transform nuclear medicine practice, enabling more personalized diagnostics and radiotheranostic strategies in the era of precision healthcare.","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0